HSBC Research Lowers GIANT BIOGENE's Target Price to HKD46.4, Maintains Buy Rating

The analyst rating for GIANT BIOGENE (02367.HK) is maintained as a "Buy" despite short-term sales pressure during the Double 11 period. This decision is based on the company's strategic adjustments, including a focus on preserving price levels and consumer experience, as well as increasing the proportion of self-broadcast channels. These actions are seen as laying a foundation for long-term growth. However, the revenue growth rate for 2025 and 2026 has been revised downward due to the sales miss, leading to a target price adjustment to HKD53.89.

The analyst rating for GIANT BIOGENE (02367.HK) is positive due to several key factors highlighted in the article. CICC views the company's plan to repurchase up to 104 million shares as a demonstration of management's confidence in the business. They believe that GIANT BIOGENE's strong R&D capabilities, brand recognition, and team cohesion will enable the company to enhance its operations by optimizing its product structure and adjusting operational strategies effectively. Additionally, the anticipated growth in its second curve medical beauty business contributes to CICC's optimistic outlook on the company's medium- to long-term growth potential, positioning it as a leader in recombinant collagen.

The analyst rating from CICC for GIANT BIOGENE (02367.HK) is based on several positive factors. They view the company's plan to repurchase up to 104 million shares as a sign of management's confidence. Additionally, CICC highlights the company's solid research and development capabilities, strong brand recognition, and team cohesion. They believe that GIANT BIOGENE can enhance its operations through product structure optimization and strategic adjustments, particularly in its growing medical aesthetics business. CICC remains optimistic about the company's mid-to-long term growth potential as a leader in recombinant collagen, which supports their Outperform rating, despite a 20% cut in the target price to HKD56.

The analyst rating from BofA Securities for GIANT BIOGENE is maintained at "Buy" despite lowering revenue and net profit forecasts for 2025-2027. The reason for this rating is the expectation that a newly approved injectable medical aesthetics product will serve as a new growth driver for the company in the upcoming year.